Advertisement

Drugs

pp 1–7 | Cite as

Revefenacin: First Global Approval

  • Young-A Heo
AdisInsight Report
  • 107 Downloads

Abstract

Revefenacin (YUPELRI™) inhalation solution, a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD). In November 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD. This article summarizes the milestones in the development of revefenacin leading to this first global approval.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Young-A Heo is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest

References

  1. 1.
    Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2018. http://goldcopd.org/. Accessed 20 Nov 2018.
  2. 2.
    Pudi KK, Barnes CN, Moran EJ, et al. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017;18(1):182.CrossRefGoogle Scholar
  3. 3.
    Mylan. YUPELRITM (revefenacin): US prescribing information. 2018. http://www.fda.gov. Accessed 13 Nov 2018.
  4. 4.
    Theravance Biopharma. Theravance Biopharma and Mylan receive FDA approval for YUPELRI™ (revefenacin) in adults with chronic obstructive pulmonary disease [media release]. 9 Nov 2018.Google Scholar
  5. 5.
    Theravance. Theravance announces clinical results in the LAMA respiratory program for the treatment of COPD [media release]. 14 July 2008.Google Scholar
  6. 6.
    Theravance. Theravance, Inc. and Theravance Biopharma, Inc. announce completion of separation of late-stage partnered respiratory assets from Biopharmaceutical operations [media release]. 2 June 2014.Google Scholar
  7. 7.
    Theravance Biopharma, Mylan. Theravance Biopharma and Mylan partner to develop and commercialize a novel LAMA compound, TD-4208, for COPD [media release]. 2 Feb 2015.Google Scholar
  8. 8.
    Theravance Biopharma. Theravance Biopharma and Mylan initiate phase 3 program for revefenacin (TD-4208) for treatment of chronic obstructive pulmonary disease (COPD) [media release]. 14 Sept 2015.Google Scholar
  9. 9.
    Hegde SS, Pulido-Rios MT, Luttmann MA, et al. Pharmacological properties of revefenacin (TD-4208), a novel, nebulized long-acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues. Pharmacol Res Perspect. 2018.  https://doi.org/10.1002/prp2.400.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Pulido-Rios MT, McNamara A, Obedencio GP, et al. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models. J Pharmacol Exp Ther. 2013;346(2):241–50.CrossRefGoogle Scholar
  11. 11.
    Donohue J, Feldman G, Sethi S, et al. Cardiovascular safety of revefenacin for nebulization: a review of randomized controlled trial data [abstract]. Chest. 2018;154(4 Suppl):734A–5A.CrossRefGoogle Scholar
  12. 12.
    Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized, double-blind, phase 2 studies. Pulm Pharmacol Ther. 2018;48:71–9.CrossRefGoogle Scholar
  13. 13.
    Lo A, Borin MT, Bourdet DL. Sequential modeling of the population pharmacokinetics of revefenacin and its major metabolite in COPD patients [abstract no. M-015]. J Pharmacokinet Pharmacodyn. 2018;45(Suppl 1):S9.Google Scholar
  14. 14.
    Bourdet D, Yeola S, Colson P, et al. Absorption, distribution, metabolism, and excretion of revefenacin, a long-acting muscarinic antagonist (LAMA), in healthy male subjects [abstract no. A3033]. Am J Respir Crit Care Med. 2018;197:A3033.Google Scholar
  15. 15.
    Theravance Biopharma. Revefenacin (TD-4208) phase 3 efficacy results. [media release]. 13 Nov 2016.Google Scholar
  16. 16.
    Ferguson GT, Pudi KK, Pendyala S, et al. Efficacy of revefenacin, a novel once-daily nebulized long-acting muscarinic antagonist: Results of two randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe chronic obstructive pulmonary disease [abstract no. A5474]. Am J Respir Crit Care Med. 2017;195:A5474.Google Scholar
  17. 17.
    Theravance Biopharma, Mylan. Theravance Biopharma and Mylan report positive new data from multiple studies of YUPELRI(T) (revefenacin) at the 2018 CHEST annual meeting [media release]. 11 Oct 2018.Google Scholar
  18. 18.
    Donohue J, Pendyala S, Barnes C, et al. The 24-hour profile of FEV1 after 12-weeks treatment with revefenacin, a once daily long-acting muscarinic receptor antagonists for nebulization: a spirometry substudy [abstract]. Chest. 2017;152(4 Suppl):A770.CrossRefGoogle Scholar
  19. 19.
    Donohue J. COPD exacerbations in the phase 3 revefenacin clinical trial program [abstract]. In: 28th Annual Congress of the European Respiratory Society. 2018.Google Scholar
  20. 20.
    Donohue J, Pendyala S, Barnes C, et al. Improvements in health status with revefenacin, a once-daily long-acting muscarinic antagonist for nebulization: changes in St George’s respiratory questionnaire and COPD assessment test in replicate 3-month studies [abstract]. Chest. 2017;152(4 Suppl):A819.CrossRefGoogle Scholar
  21. 21.
    Mahler D, Ohar J, Barnes C, et al. Efficacy of revefenacin by nebulization and tiotropium by HandiHaler® in subjects with COPD and suboptimal peak inspiratory flow rates (PIFR) [abstract]. Chest. 2018;154(4):732A–3A.CrossRefGoogle Scholar
  22. 22.
    Theravance Biopharma, Mylan. Theravance Biopharma and Mylan report new data from phase 3 studies of YUPELRI(Tm) (revefenacin) in oral presentation at the European Respiratory Society International Congress [media release]. 17 Sept 2018.Google Scholar
  23. 23.
    Kerwin EM, Donohue JF, Sethi S, et al. Revefenacin, a once-daily, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease (COPD): results of a 52-week safety and tolerability phase 3 trial in participants with moderate to very severe COPD [abstract no. A4239]. Am J Respir Crit Care Med. 2018;197:A4239.Google Scholar
  24. 24.
    Feldman G, Barnes CN, Moran EJ, et al. Safety and tolerability of revefenacin, a novel once-daily nebulized long-acting muscarinic antagonist: results of two 12-week, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe chronic obstructive pulmonary disease [abstract no. A3598]. Am J Respir Crit Care Med. 2017;195:A3598.Google Scholar
  25. 25.
    Theravance Biopharma. Theravance Biopharma and Mylan report additional phase 3 data for revefenacin (TD-4208) in several presentations at 2017 ATS [media release]. 23 May 2017.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations